These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 31898687)

  • 1. Cost-risk analysis of available cervix cancer vaccine: Situation analysis from Thailand.
    Wiwanitkit S; Wiwanitkit V
    J Cancer Res Ther; 2019; 15(6):1421. PubMed ID: 31898687
    [No Abstract]   [Full Text] [Related]  

  • 2. For debate: that Australia should continue using the quadrivalent vaccine.
    Wain G
    Sex Health; 2010 Sep; 7(3):235-7. PubMed ID: 21058496
    [No Abstract]   [Full Text] [Related]  

  • 3. Preventive vaccination against cervical cancer: Korean Society of Gynecologic Oncology Guideline.
    Min KJ; Kwon SH; Kim S; Kim HJ; Seong SJ; Song YJ; Shin JW; Lee KH; Lim MC; Chung HH; Ju W; Hong JH; Lee JW; Kim JW; Bae DS; Lee JK
    J Gynecol Oncol; 2016 May; 27(3):e30. PubMed ID: 27029751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HPV vaccine strategies: the cost of HPV and the choice of vaccine.
    Morris SR
    Sex Transm Infect; 2009 Sep; 85(5):315-6. PubMed ID: 19773455
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule.
    Germar MJ; Purugganan C; Bernardino MS; Cuenca B; Chen YC; Li X; Van Kriekinge G; Lee IH
    Hum Vaccin Immunother; 2017 May; 13(5):1158-1166. PubMed ID: 28075249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States.
    Brisson M; Laprise JF; Chesson HW; Drolet M; Malagón T; Boily MC; Markowitz LE
    J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26438574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of HPV vaccination in Belize.
    Walwyn L; Janusz CB; Clark AD; Prieto E; Waight E; Largaespada N
    Vaccine; 2015 May; 33 Suppl 1():A174-81. PubMed ID: 25919158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis.
    Simms KT; Laprise JF; Smith MA; Lew JB; Caruana M; Brisson M; Canfell K
    Lancet Public Health; 2016 Dec; 1(2):e66-e75. PubMed ID: 29253419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Unethical to continue to promote the HPV vaccine].
    Gerdes S
    Ugeskr Laeger; 2013 Oct; 175(41):2442. PubMed ID: 26495460
    [No Abstract]   [Full Text] [Related]  

  • 10. (Not) warts and all.
    Hammond P
    BMJ; 2008 Oct; 337():a2186. PubMed ID: 18948345
    [No Abstract]   [Full Text] [Related]  

  • 11. HPV single-dose vaccination: Impact potential, evidence base and further evaluation.
    Stanley M; Dull P
    Vaccine; 2018 Aug; 36(32 Pt A):4759-4760. PubMed ID: 29754700
    [No Abstract]   [Full Text] [Related]  

  • 12. HPV Vaccine Slashes Rates of Oral Infection.
    Cancer Discov; 2017 Jul; 7(7):OF6. PubMed ID: 28526738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of controlling cervical cancer using a new 9-valent human papillomavirus vaccine among school-aged girls in Australia.
    Mahumud RA; Alam K; Dunn J; Gow J
    PLoS One; 2019; 14(10):e0223658. PubMed ID: 31596899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mandating a human papillomavirus vaccine: an investigation into whether such legislation is constitutional and prudent.
    Dowling TS
    Am J Law Med; 2008; 34(1):65-84. PubMed ID: 18512537
    [No Abstract]   [Full Text] [Related]  

  • 15. [Anti-HPV vaccines: they are proven to be safe and do not provoke autoimmune diseases].
    Nau JY
    Rev Med Suisse; 2015 Sep; 11(487):1770-1. PubMed ID: 26591793
    [No Abstract]   [Full Text] [Related]  

  • 16. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
    McCormack PL; Joura EA
    BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies Find Single Dose of HPV Vaccines May Be Effective.
    Larkin HD
    JAMA; 2022 Nov; 328(19):1896. PubMed ID: 36378200
    [No Abstract]   [Full Text] [Related]  

  • 18. Quadrivalent human papillomavirus vaccine.
    Barr E; Tamms G
    Clin Infect Dis; 2007 Sep; 45(5):609-7. PubMed ID: 17682997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil): profile report.
    Siddiqui MA; Perry CM
    BioDrugs; 2006; 20(5):313-6. PubMed ID: 17025377
    [No Abstract]   [Full Text] [Related]  

  • 20. Quadrivalent human papillomavirus recombinant vaccine: the first vaccine for cervical cancers.
    Sharma R; Sharma CL
    J Cancer Res Ther; 2007; 3(2):92-5. PubMed ID: 17998730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.